Summary

Adalimumab and Vedolizumab are two of the targeted treatments for ulcerative colitis, which may be used as the drugs of initial choice (if conventional therapy was inefficient or is not tolerated), and in the case of primary nonresponse or loss of efficacy of another targeted therapy. Although we are aware that biological agents can be associated with various dermatological side effects, the development of psoriasiform dermatitis induced by the separate administration of two types of biologics has been narrowly described and, to our knowledge, has never been reported before only after dose escalation of biologic drugs. We report a case of a drug reaction consisting of psoriasiform dermatitis in a female patient treated with biologics for ulcerative colitis, highlighting the aspect that these cutaneous manifestations appeared only after dose optimization of biological agents.